Search
Mainz Biomed NV
MYNZAdd to Watchlist
0.844USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
35.06MMarket Cap
LossP/E TTM
More Details of Mainz Biomed NV Company
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Mainz Biomed NV Info
Ticker SymbolMYNZ
Company nameMainz Biomed NV
IPO dateNov 04, 2021
CEOBaechler (Guido)
Number of employees19
Security typeOrdinary Share
Fiscal year-endNov 04
AddressSirius Gutenberg Park
CityMAINZ
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code55129
Phone496131265140
Websitehttps://www.mainzbiomed.com/
Ticker SymbolMYNZ
IPO dateNov 04, 2021
CEOBaechler (Guido)
Company Executives of Mainz Biomed NV
Name
Name/Position
Position
Shareholding
Change
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
64.50K
+96.59%
Mr. Hans Hekland
Mr. Hans Hekland
Non-Executive Independent Director
Non-Executive Independent Director
56.00K
+68.27%
Mr. Gregory J. (Greg) Tibbitts
Mr. Gregory J. (Greg) Tibbitts
Non-Executive Independent Director
Non-Executive Independent Director
55.88K
+17.90%
Mr. Guido Baechler
Mr. Guido Baechler
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36K
-9410.50%
Dr. Chris von Toerne
Dr. Chris von Toerne
Chief Operating Officer
Chief Operating Officer
2.50K
+93.24%
Mr. William Caragol
Mr. William Caragol
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
64.50K
+96.59%
Mr. Hans Hekland
Mr. Hans Hekland
Non-Executive Independent Director
Non-Executive Independent Director
56.00K
+68.27%
Mr. Gregory J. (Greg) Tibbitts
Mr. Gregory J. (Greg) Tibbitts
Non-Executive Independent Director
Non-Executive Independent Director
55.88K
+17.90%
Mr. Guido Baechler
Mr. Guido Baechler
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36K
-9410.50%
Dr. Chris von Toerne
Dr. Chris von Toerne
Chief Operating Officer
Chief Operating Officer
2.50K
+93.24%
Mr. William Caragol
Mr. William Caragol
Chief Financial Officer
Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of Mainz Biomed NV?
The top five shareholders of Mainz Biomed NV are: Dr. Heiner Dreismann, Ph.D.
How many institutions hold shares of Mainz Biomed NV (MYNZ)?
As of 2026Q1, 33 institutions hold shares of Mainz Biomed NV, with a combined market value of approximately 1.23M, accounting for 9.84% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 663009.00.